Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients with Atrial Cardiopathy, The ARCADIA Randomized Clinical Trial
JAMA 331:573-581, Kamel,H.,et al, 2024
Perioperative Management of Anticoagulant and Antiplatelet Therapy
NEJM Evid doi:10.1056/EVIDna2200322, Douketis,J.D. & Spyropoulos,A.C., 2023
Cerebral Venous Thrombosis
NEJM 385:59-64, Ropper, A.H. & Kline, J.P., 2021
Stroke Prevention by Anticoagulants in Daily Practice Depending on Atrial Fibrillation Pattern and Clinical Risk Factors
Stroke 52:3121-3131, Grimaldi-Bensouda, L.,et al, 2021
Clinical Outcomes in Atrial Fibrillation Patients with a History of Cancer Treated with Non-Vitamin K Antagonist Oral Anticoagulants
Stroke 52:3132-3141, Chan, Y.H.,et al, 2021
Left Ventricular Dysfunction Among Patients with Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin
JAMA Neurol 78:1454-1460, Merkler, A.E.,et al, 2021
Safety of Intravenous Thrombolysis Among Patients Taking Direct Oral Anticoagulants
Stroke 51:533-541, Shahjouei, S.,et al, 2020
MT in Anticoagulated Patients
Neurol 94: e842-e850, LAllinec, V.,et al, 2020
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
NEJM 382:1599-1607,1650, Agnelli, G.,et al, 2020
Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events with Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients with Atrial Fibrillation with a History of Intracranial Hemorrhage
JAMA Network Open 3:e206424, Tsai, C.T.,et al, 2020
Convexity Subarachnoid Hemorrhage Soon after Starting a Direct Oral Anticoagulant in 2 Patients with Acute Infarction
J Stroke Cerebrovasc Dis 29:105216, Jugita, Y.,et al, 2020
Cerebral Ischemia in Patients on Direct Oral Anticoagulants
Stroke 50:873-879, Macha, K.,et al, 2019
Clinical Effectiveness of Direct Oral Anticoagulations vs Warfarin in Older Patients with Atrial Fibrillation and Ischemic Stroke
JAMA Neurol 76:1192-1202, Xian, Y.,et al, 2019
Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared with Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation
Stroke 49:1464-1470, Reddy, V.Y.,et al, 2018
Factor Xa Inhibitors Versus Vitamin K Antagonists for Prevention of Cerebral or Systemic Embolism in Patients with Atrial Fibrillation
Stroke 49:e235-e236, Bruins Slot, K.M.H. & Berge, E., 2018
Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients with Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke
Stroke 49:2237-2240, Jin, C.,et al, 2018
Coagulation Test Interpretation in a Patient Taking Direct Oral Anticoagulant Therapy
JAMA 320:1485-1486, Sholzberg, M. & Xu, Y., 2018
Association of Antithrombotic Drug Use with Subdural Hematoma Risk
JAMA 317:836-846, Gaist, D.,et al, 2017
Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents
Stroke 48:1432-1437, Steiner, T.,et al, 2017
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
NEJM 376:1627-1636, Calkins, H.,et al, 2017
Outcome of Intracerebral Hemorrhage Associated with Different Oral Anticoagulants
Neurol 88:1693-1700,1686, Wilson, D.,et al, 2017
Intravenous Thrombolysis in Acute Ischemic Stroke Patients Pretreated with Non-Vitamin K Antagonist Oral Anticoagulants
Stroke 48:2031-2033, Tsivgoulis, G. & Safouris, A., 2017
Should Patients with Ischemic Stroke or Transient Ischemic Attack with Atrial Fibrillation and Microbleeds be Anticoagulated?
Stroke 48:3408-3412, Shoamanesh, A.,et al, 2017
Treatment of Cryptogenic Stroke with Active Cancer with a New Oral Anticoagulant
J Stroke Cerebrovasc Dis 26:2976-2980, Nam, K.W.,et al, 2017
Oral Anticoagulants for Prevention of Stroke in Atrial Fibrillation: Systematic Review, Network Meta-Analysis, and Cost Effectiveness Analysis
BMJ 359:J5058, Lopez-Lopez, J.A.,et al, 2017
Is it Necessary to Alter Anticoagulation Therapy for Tooth Extraction in Patients Taking Direct Oral Anticoagulants?
Med Oral Patol Oral Cir Bucal 22:e767-e773, Caliskan, M.,et al, 2017
Early Clinical and Radiological Course, Management, and Outcome of Intracerebral Hemorrhage Related to New Oral Anticoagulants
JAMA Neurol 73:169-177,155, Purrucker, J.C.,et al, 2016
Embolic Stroke, Atrial Fibrillation, and Microbleeds
Stroke 47:904-907, Diener, H-C.,et al, 2016
Which Oral Anticoagulation for Atrial Fibrillation?
JAMA 315:2117-2118, The Medical Letter, 2016
Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients
Stroke 47:1555-1561, Shah, A.,et al, 2016
Primary Prevention of Stroke
JAMA 316:658-659, Steiger, N. & Cifu, A.S., 2016
Stability of International Normalized Ratios in Patients Taking Long-Term Warfarin Therapy
JAMA 316:661-662, Pokorney, S.D.,et al, 2016
Trousseaus Syndrome: Cancer-Associated Thrombosis
Jpn J Clin Oncol 46:204-207, Ikushima, S.,et al, 2016
Risk of Gastrointestinal Bleeding Associated with Oral Anticoagulants: Population Based Retrospective Cohort Study
BMJ 350:h1585, h1679, Chang, H.Y.,et al, 2015
Comparative Risk of Gastrointestinal Bleeding with Dabigatran, Rivaroxaban, and Warfarin: Population Based Cohort Study
BMJ 350:h1857, h1979, Abraham, N.S.,et al, 2015
Stroke Prevention in Atrial Fibrillation
JAMA 313:1950-1962, Lip, G.Y.H. & Lane, D.A., 2015
Peri-Procedural Management of Patients Taking Oral Anticoagulants
BMJ 351:h2391, Daniels, P.R., 2015
Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: Current Status, Special Situations, and Unmet Needs
Lancet 386:303-310, Verheugt, F.W.A. & Granger, C.B., 2015
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
NEJM 373:2413-2424,2471, Siegal, D.M.,et al, 2015
Endovascular Treatment for Acute Ischemic Stroke in the Setting of Anticoagulation
Stroke 46:3536-3539, Rebello, L.C.,et al, 2015
Summary of Evidence-Based Guideline Update: Prevention of Stroke in Nonvalvular Atrial Fibrillation
Neurol 82:716-724, Culebras, A.,et al, 2014
Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials
Lancet 383:955-962,931, Ruff, C.T.,et al, 2014
Subdural Haematoma in the Elderly
BMJ 348:g1682, Teale, E.A.,et al, 2014
Rethinking Warfarin for Atrial Fibrillation
JAMA 311:1246, Zuccott, G & Pflomm, J.M., 2014
Factor Xa Inhibitors vs Warfarin for Preventing Stroke and Thromboembolism in Patients with Atrial Fibrillation
JAMA 311:1150-1151, Bruins Slot, K.M.H. & Berge, E., 2014
Novel Factor Xa Inhibitor for the Treatment of Cerebral Venous and Sinus Thrombosis
Stroke 45:2469-2471, Geisbusch, C.,et al, 2014
Intracranial Hemorrhage Mortality in Atrial Fibrillation Patients Treated with Dabigatran or Warfarin
Stroke 45:2286-2291, Alonso, A.,et al, 2014
Cerebrovascular Events in 21 105 Patients with Atrial Fibrillation Randomized to Edoxaban Versus Warfarin
Stroke 45:2372-2378, Giugliano, R.P.,et al, 2014
Association of Cerebral Microbleeds with Mortality in Stroke Patients Having Atrial Fibrillation
Neurol 83:1308-1315,1304, Song, T.J.,et al, 2014